Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this
study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in
subjects with rheumatoid arthritis already receiving methotrexate